Journal of Nuclear Medicine: 55 (12)

About the Cover

December 1, 2014; Volume 55,Issue 12

Cover image

¹⁸F-mefway exhibits favorable in vivo properties for serotonin 5-HT_1A receptor measurements in humans. It is an attractive PET radiotracer for neuropsychiatric disorders and drug intervention. See page 1973.

In this issue

Issue highlights

Perceived Misinterpretation Rates in Oncologic ¹⁸F-FDG PET/CT Studies: A Survey of Referring Physicians
Comparison and Prognostic Validation of Multiple Methods of Quantification of Myocardial Blood Flow with ⁸²Rb PET
First-in-Human Evaluation of ¹⁸F-Mefway, a PET Radioligand Specific to Serotonin-1A Receptors
Multimodality Imaging of Alzheimer Disease and Other Neurodegenerative Dementias

First-in-Human Assessment of ¹¹C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer
Performance Evaluation of the uEXPLORER Total-Body PET/CT Scanner Based on NEMA NU 2-2018 with Additional Tests to Characterize PET Scanners with a Long Axial Field of View
Slow but Evident Recovery from Neocortical Dysfunction and Cognitive Impairment in a Series of Chronic COVID-19 Patients
Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns
Is FDG maximum standardized uptake value (SUV max) of primary breast cancer can predict axillary lymph node metastasis?

More...

Main menu

User menu

Search

About the Cover

Cover image

In this issue

Issue highlights

Jump to